Skip to main content

Advertisement

Figure 6 | Molecular Cancer

Figure 6

From: Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells

Figure 6

In vivo anti-tumor activity of D1 and D6. (A), (B): in the melanoma animal model, nude mice (n = 8 mice/group) received i.v. 17.5 mg/kg of D1 and D6 or saline solution (control mice) on day 5 after s.c. injection of 1.5 × 106 LB24 cells, twice a week, for 7 times. (A) Tumor volumes were measured at different times points after cell inoculation. P values were calculated using Peto's log-rank test (**, P < 0.01; ***, P < 0.001). Inset: absolute mean body weight, in grams, after the beginning of the treatment. (B) Two days after the end of the treatment, mice were sacrificed and tumors were excised and weighted. Bars depict the mean values and error bars represent 95% confidence intervals. P values were calculated using ANOVA with Tukey's multiple comparison test (*, P < 0.05; ***, P < 0.001). (C): Nude mice were orthotopically injected with 1.5 × 106 luciferase-transfected GI-LI-N neuroblastoma cells and tumors were allowed to grow for 14 days, then mice, randomly assigned to three groups (5 mice/group), were treated with the same schedule used for the above melanoma animal model. Orthotopic tumor growth was monitored over time by bioluminescence imaging (BLI). P values were calculated using Peto's log-rank test (***, P < 0.001). Inset: absolute mean body weight, in grams, after the beginning of the treatment. (D) Therapeutic effects on survival were evaluated on nude mice (n = 8 mice/group) orthotopically injected with 1.5 × 106 GI-LI-N cells in the left adrenal gland and treated as above. Survival of mice was monitored daily. P = 0.0007 for D6 over control and P = 0.0169 for D6 over D1.

Back to article page